Utility of pleural fluid for predictive marker testing in malignant pleural effusion
J. Ferguson (Glasgow, United Kingdom), C. Craig (Manchester, United Kingdom), V. Randles (Cheshire, United Kingdom), T. Taylor (Cheshire, United Kingdom), L. Brown (Manchester, United Kingdom), D. Fullerton (Cheshire, United Kingdom), M. Evison (Manchester, United Kingdom), K. Blyth (Glasgow, United Kingdom), S. Tsim (Glasgow, United Kingdom)
Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications
Disease area: Thoracic oncology
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Ferguson (Glasgow, United Kingdom), C. Craig (Manchester, United Kingdom), V. Randles (Cheshire, United Kingdom), T. Taylor (Cheshire, United Kingdom), L. Brown (Manchester, United Kingdom), D. Fullerton (Cheshire, United Kingdom), M. Evison (Manchester, United Kingdom), K. Blyth (Glasgow, United Kingdom), S. Tsim (Glasgow, United Kingdom). Utility of pleural fluid for predictive marker testing in malignant pleural effusion. 4493
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: